ANI Pharmaceuticals (ANIP) announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the ...

PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets ...

Shares of NASDAQ ANIP opened at $62.49 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a 52 week low of $52.50 ...

ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of ...

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full ...

Christopher Mutz; Senior Vice President, Head of Rare Diseases; ANI Pharmaceuticals Inc Stephen Carey; Chief Financial Officer, Senior Vice President; ANI Pharmaceuticals Inc Good morning everyone.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript February 28, 2025 ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.63, expectations were $1.41.

ANI Pharmaceuticals' Q4 adjusted EPS rose to $1.63, beating estimates of $1.44, with sales up 44.8% year-over-year to $190.57 million. 2025 guidance raised: revenue expected at $756M-$776M vs.

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2024, with sales up 44.8% year on year to $190.6 million. The company’s full-year ...

BAUDETTE, Minn., March 14, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an ...